



03C0

PATENT
TECH CENTER 1600/2900
5

Case Docket No. GENENT.083A
Date: October 24, 2001

DEC 04 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Pennica et al.

Appl. No. : 09/901,812

Filed : July 10, 2001

For : METHODS FOR
ENHANCING THE
EFFICACY OF CANCER
THERAPY

Examiner : Unknown

Group Art Unit : 1645

I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first class mail in
an envelope addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231, on

October 24, 2001

(Date)

Ginger R. Dreger, Reg. No. 33,055

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231
ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with 302 references.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Ginger R. Dreger
Registration No. 33,055
Attorney of Record

GENENT.083A



TECH CENTER 1600/2900

PATENT
DEC 04 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pennica et al.) Group Art Unit 1645
App. No. : 09/901,812)
Filed : July 10, 2001)
For : METHODS FOR)
ENHANCING THE)
EFFICACY OF CANCER)
THERAPY)
Examiner : Unknown

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct 06, 2001

By: Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1. 3,773,919	11.20.73	Boswell et al.			
	2. 4,179,337	12.18.79	Davis et al.			
	3. 4,275,149	6.23.81	Litman et al.			
	4. 4,399,216	8.16.83	Axel et al.			
	5. 4,485,045	11.27.84	Regen			
	6. 4,496,689	1.20.85	Mitra			
	7. 4,544,545	10.1.85	Ryan et al.			
	8. 4,640,835	2.3.87	Shimizu et al.			
	9. 4,657,760	4.14.87	Kung et al.			
	10. 4,670,417	6.2.87	Iwasaki et al.			
	11. 4,676,980	6.30.87	Segal et al.			
	12. 4,736,866	4.12.88	Leder et al.			
	13. 4,791,192	12.13.88	Nakagawa et al.			
	14. 4,816,567	3.28.89	Cabilly et al.			
	15. 4,870,009	9.26.89	Evans et al.			
	16. 4,873,191	10.10.89	Wagner et al.			
	17. 4,943,529	7.24.90	Van Den Berg et al.			
	18. 4,975,278	12.4.90	Senter et al.			
	19. 5,010,182	4.23.91	Brake et al.			
	20. 5,013,556	5.7.91	Woodle et al.			
	21. 5,122,469	6.16.92	Mather et al.			
	22. 5,206,344	4.27.93	Katre et al.			
	23. 5,225,212	7.6.93	Martin et al.			
	24. 5,428,130	6.27.95	Capon et al.			
	25. 5,545,806	8.13.96	Lonberg et al.			
	26. 5,545,807	8.13.96	Surani et al.			

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Pennica et al	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE July 10, 2001	GROUP 1645



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	27. 5,569,825	10.29.96	Lonberg et al.			
	28. 5,625,126	4.29.97	Lonberg et al.			
	29. 5,633,425	5.27.97	Lonberg et al.			
	30. 5,654,010	8.5.97	Johnson et al.			
	31. 5,661,016	8.26.97	Lonberg et al.			
	32. 6,187,819	2.13.01	Fisher et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	33. EP 03089	05.30.90	EP				
	34. EP 117,058	08.29.84	EP				
	35. EP 117,060	08.29.84	EP				
	36. EP 139,383	05.02.85	EP				
	37. EP 307,247	03.15.88	EP				
	38. EP 36,776	09.30.81	EP				
	39. EP 362,179	04.04.90	EP				
	40. EP 394,538	10.31.90	EP				
	41. EP 404,097	12.27.90	EP				
	42. EP 616,812	09.28.94	EP				
	43. EP 073,657	03.09.83	EP				
/	44. WO 81/01145	4.20.81	PCT				
/	45. WO 87/05330	9.11.87	PCT				
/	46. WO 84/03564	9.13.94	PCT				
	47. WO 88/07378	10.6.88	PCT				
	48. WO 89/05859	6.29.89	PCT				
	49. WO 90/10048	9.7.90	PCT				
/	50. WO 90/13641	11.15.90	PCT				

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT DEC 03 2001 (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/	51. WO 90/13646	11.15.90	PCT				
/	52. WO 91/00357	1.10.91	PCT				
/	53. WO 91/00360	1.10.91	PCT				
/	54. WO 91/04753	4.18.91	PCT				
/	55. WO 93/11161	6.10.93	PCT				
/	56. WO 93/17041	9.2.93	PCT				
/	57. WO 93/18186	9.16.93	PCT				
/	58. WO 94/11026	5.26.94	PCT				
/	59. WO 96/07399	3.14.96	PCT				
/	60. WO 96/27011	9.6.96	PCT				
/	61. WO 96/40072	12.19.96	PCT				
/	62. WO 97/03692	2.6.97	PCT				
/	63. WO 99/47162	9.23.99	PCT				
/	64. WO 97/33551	9.18.97	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
65.	Alitalo and Schwab "Oncogene Amplification in Tumor Cells" <u>Adv. Cancer Res.</u> , 47:235-281 (1986)
66.	Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs" <u>Nucleic Acids Res.</u> 25(17):3389-3402 (1997)
67.	Anderson et al., "Direct Interactions of Coxsakievirus B3 with Immune Cells in the Splenic Compartment of Mice Susceptible or Resistant to Myocarditis" <u>Science</u> 256, 808-813 (1992)
68.	Aquino et al., "Effect of the Combined Treatment with 5-Fluorouracil, γ -Interferon or Folinic Acid on Carcinoembryonic Antigen Expression in Colon Cancer Cells" <u>Clinical Cancer Research</u> , 4(10): 2473-2481 (Oct. 1998)
69.	Athauda et al., "Entrapment and Inhibition of Human Immunodeficiency Virus Proteinase by a α 2-Macroglobulin and Structural Changes in the Inhibitor" <u>J. Biochem.</u> , 113:742-746 (1993)
70.	Ausubel et al., <u>Current Protocols of Molecular Biology</u> , John Wiley and Sons (1997)
71.	Barker et al., "The Yin-Yang of TCF/ β -Catenin Signaling" <u>Adv Cancer Res</u> 77:1-24 (2000)
72.	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185her2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> , 14:737-744 (1996)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 O P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>DEC 03 2001</i> (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL <i>PATENT & TRADEMARK OFF</i>	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	73.	Baselga et al., "HER2 Overexpression and Paclitaxel Sensitivity in Breast Cancer: Therapeutic implications" <u>Oncology</u> , 11 (3 Suppl):43-48 (1997)	
	74.	Beach and Nurse, "High-frequency transformation of the fission yeast <i>Schizosaccharomyces pombe</i> " <u>Nature</u> , 290: 140 (1981)	
	75.	Beal and Dervan et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" <u>Science</u> , 251:1360 (1991)	
	76.	Beckmann, et al., "Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors" <u>EMBO J</u> 13:3657 (1994)	
	77.	Behrens, et al., "Functional Interaction of β-catenin with the transcription factor LEF-1" <u>Nature</u> 382:638-642 (1996)	
	78.	Bergstein et al., "Isolation of Two Novel WNT Genes, WNT14 AND wnt15, One of Which (WNT15) Is Closely linked to WNT3 on Human Chromosome 17q21" <u>Genomics</u> 46:450-458 (1997)	
	79.	Bidyut Roy et al., "Synergistic Activation of Retinoic Acid (RA)-Responsive Genes and Induction of Embryonal Carcinoma Cell Differentiation by a RA Receptor α (RARα)-, RARβ-, or RARγ-Selective Ligand in Combination with a Retinoid X Receptor-Specific Ligand" <u>Mol. Cell. Biol.</u> , 15(12):6481-7 (1995)	
	80.	Bishop, Michael J., "Molecular Themes in Oncogenesis" <u>Cell</u> , 64:235-248 (1991)	
	81.	Boerner et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes" <u>J. Immunol.</u> , 147(1):86-95 (1991)	
	82.	Bolivar et al., "Construction and characterization of new cloning vehicles" <u>Gene</u> , 2:95-113 (1977)	
	83.	Boring et al., "Cancer Statistics, 1993" <u>CA Cancel J. Clin.</u> , 43:7 (1993)	
	84.	Bouillet et al., "Efficient Cloning of cDNA of Retinoic Acid-Responsive Genes in P19 Embryonal Carcinoma Cells and Characterization of a Novel Mouse Gene, Stra1 (Mouse LERK-2/Eplg2)" <u>Dev. Biol.</u> 170:420-433 (1995)	
	85.	Bouillet et al., "Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein" <u>Mechanisms of Development</u> 63, 173-186 (1997)	
	86.	Boven and Winograd, eds., <u>The Nude Mouse in Oncology Research</u> , CRC Press, Inc., 1991	
	87.	Bradley, Allan, "Production and analysis of Chimaeric mice" in <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed. (IRL, Oxford, 1987), 5:113-152	
	88.	Braxton and Wells, "Incorporation of Stabilizing Ca ²⁺ -Binding Loop into Subtilisin BPN'" <u>Biochemistry</u> , 31:7796-7801 (1992)	
	89.	Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments" <u>Science</u> 229:81 (1985)	
	90.	Bui et al., "A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas" <u>Oncogene</u> 14:1249-1253 (1997)	
	91.	C. Anthony, <u>The Biochemistry of Methylotrophs</u> , 269-295 (1982)	
	92.	Caraglia et al., "5-Axa-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells" <u>Annals of Oncology</u> , 5(3):269-76 (1994)	
	93.	Caron et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies" <u>J. Exp Med.</u> , 176: 1191-1195 (1992)	
	94.	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> , 13:4331 (1986)	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
95.	Case et al., "Efficient Transformation of Neurospora crassa by Utilizing Hybrid Plasmid DNA" <u>Proc. Natl. Acad. Sci. USA</u> , 76:5259-5263 (1979)
96.	Chang et al., "Phenotype expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase" <u>Nature</u> , 275:615 (1978)
97.	Chazaud et al., "Restricted Expression of a Novel Retinoic Acid Responsive Gene During Limb Bud Dorsoventral Patterning and Endochondral Ossification" <u>Dev. Genet.</u> 19: 66-73 (1996)
98.	Chevray and Nathans, "Portein interaction cloning in yeast: Identification of mammalian proteins that react with leucine zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> , 89: 5789-5793 (1991)
99.	Chien et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest" <u>Proc. Natl. Acad. Sci. USA</u> , 88:9578-9582 (1991)
100.	Chothia, Cyrus, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>J. Mol. Biol.</u> , 150:1 (1976)
101.	Clark et al., "Molecular Cloning of the Human Proto-oncogene Wnt-5A and Mapping of the Gene (WNTSA) to Chromosome 3p14-p21" <u>Genomics</u> 18:249-260 (1993)
102.	Cleland, Jeffrey L., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, eds, (Plenum Press: New York, 1995), Chapter 18 pp. 439-462
103.	Clotman et al., "All-trans-Retinoic Acid Upregulates the Expression of COUP-TFI in Early-Somite Mouse Embryos Cultured In Vitro" <u>Neurotoxicol Teratol</u> 20:591-599 (1998)
104.	Cooney et al. 'Site-Sepcific Oligonucleotide Binding Represses transcription of the Human c-myc Gene in Vitro", <u>Science</u> , 241: 456-459 (1988)
105.	Creighton, <u>Proteins: Structure and Molecular Properties</u> , W.H. Freeman & Co., San Francisco, (1983)
106.	Cunningham and Wells, 'High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis" <u>Science</u> , 244: 1081-1085 (1989)
107.	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> , 13:1014 (1974)
108.	Davis, et al., "Ligands for EPH-Related Receptor Tyrosine Kinases That Require Membrane Attachment or Clustering for Activity" <u>Science</u> 266:816 (1994)
109.	deBoer et al., "The tac promoter: A functional hybrid derived from the trp and lac promoters" <u>Proc. Natl. Acad. Sci. USA</u> , 80:21-25 (1983)
110.	DeLeo et al., "Cell Surface Antigens of Chemically Induced Sarcomas of the Mouse" <u>J. Exp. Med.</u> , 146:720-730 (1977)
111.	Dennis et al., "A secreted Frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates Wnt-1 signaling" <u>Journal of Cell Science</u> 112:3814-3820 (1999)
112.	Deutscher, Murray P. (Ed.), <u>Methods in Enzymology</u> , 182 (1990)
113.	Donehower et al., "Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability" <u>Genes Dev</u> 9:882-895 (1995)
114.	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>PNAS USA</u> , 83:9129-9133 (1986)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 O I P E DEC 03 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
	APPLICANT Pennica et al	
	FILING DATE July 10, 2001	GROUP 1645

PATENT & TRADEMARK EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
115	Drebin et al., "Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene" <u>Nature</u> 312(5994):545-8 (1984)
116	Duester, Gregg, "Families of retinoid dehydrogenases regulating vitamin A function Production of visual pigment and retinoic acid" <u>Eur J Biochem</u> 267:4315-4324 (2000)
117	Easwaran et al., "Cross-regulation of β-catenin-LEF/TCF and retinoid signaling pathways" <u>Curr. Biol.</u> 9:1415-1418 (1999)
118	Eberhard et al., "Alterations of Annexin Expression in Pathological Neuronal and Glial Reactions" <u>Am. J. Pathol.</u> 145:640-9 (1994)
119	Edge et al. "Deglucosylation of Glycoproteins by Trifluoromethanesulfonic Acid", <u>Anal. Biochem.</u> , 118:131-137 (1981)
120	Epstein et al. "Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor", <u>Proc. Natl. Acad. Sci. USA</u> , 82: 3688 (1985)
121	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular and Cellular Biology</u> , 5:3610-3616 (1985)
122	Fear et al., "Wnt-16a, a Novel Wnt-16 Isoform, Which Shows Differential Expression in Adult Human Tissues" <u>Biochem Biophys Res Commun</u> 278:814-820 (2000)
123	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <u>Saccharomyces cerevisiae</u> by Use of an Epitope Addition Method" <u>Mol. Cell. Biol.</u> , 8:2159-2165 (1988)
124	Fields and Song, "A novel genetic system to detect protein-protein interactions" <u>Nature</u> , 340:245-246 (1989)
125	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice" <u>Nature Biotechnology</u> 14, 845-51 (1996)
126	Fleer et al., 'Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by Kluyveromyces Yeasts , <u>Bio/Technology</u> , 9:968-975 (1991)
127	Fournier and Ozeki, "Structure and Organization of the Transfer Ribonucleic Acid Genes of <u>Escherichia coli</u> K-12", <u>Microbiol. Rev.</u> 49:379-397 (1985)
128	Freund and Blair "Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated With Pristane", <u>J. Immunol.</u> 129:2826-2830 (1982)
129	Gabizon et al., "Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times" <u>J. National Cancer Inst.</u> , 81(19): 1484 (1989)
130	Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clin. Chem.</u> 43:752 (1997)
131	Gething et al., "Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene" <u>Nature</u> , 293:620-625 (1981)
132	Glennie and Johnson, "Clinical trials of antibody therapy" <u>Immunol Today</u> 21: 403-410 (2000)
133	Goeddel et al., "Direct expression in <u>Escherichia coli</u> of a DNA sequence coding for human growth hormone" <u>Nature</u> , 281:544 (1979)
134	Goeddel et al., "Synthesis of human fibroblast by <u>E. coli</u> " <u>Nucleic Acids Res.</u> , 8:4057 (1980)
135	Graham et al. "Characteristics of a Human Cell Line Transformed by DNA from human Adenovirus Type 5", <u>J. Gen Virol.</u> , 36:59 (1977)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT DEC 03 2001 (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL PATENT & TRADEMARK	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	136	Gray et al. "Fluorescence In Situ Hybridization in Cancer and Radiation Biology", <u>Radiation Res.</u> , 137:275-289 (1994)	
	137	Gruber et al "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Express in Escherichia coli", <u>J. Immunol.</u> 152:5368 (1994)	
	138	He et al., "Identification of c-MYC as a Target of the APC Pathway" <u>Science</u> 281:1509-1512 (1998)	
	139	Hess et al., "Cooperation of Glycolytic Enzymes", <u>J. Adv. Enzyme Reg.</u> , 7:149 (1968)	
	140	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by Immunological Screening Technique" <u>J. Biol. Chem.</u> , 255:2073 (1980)	
	141	Hodgson, John, "Data-Directed Drug Design" <u>Bio/Technology</u> , 9: 19-21 (1991)	
	142	Holland and Holland, "Isolation and Identification of yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase and Phosphoglycerate Kinase" <u>Biochemistry</u> , 17:4900-4907 (1978)	
	143	Hollinger et al., "Diabodies": Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> , 90:6444-6448 (1993)	
	144	Hongo et al."Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β ", <u>Hybridoma</u> 14:253-260 (1995)	
	145	Hopp et al., "A short polypeptide marker sequence useful for recombinant protein identification and purification" <u>BioTechnology</u> , 6:1204-1210 (1988)	
	146	Hora et al., "Controlled Release of Interleukin-2 From Biodegradable Microspheres", <u>Bio/Technology</u> , 8:755-758 (1990)	
	147	Hsiao et al., "High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene" <u>Proc. Natl. Acad. Sci. (USA)</u> , 76:3829 (1979)	
	148	Huguet et al., "Differential Expression of Human Wnt Genes 2,3,4, and 7B in Human Breast Cell Lines and Normal and disease States of Human Breast Tissue" <u>Cancer Res</u> 54:2615-2521 (1994)	
	149	Hunter, Tony, "Cooperation between Oncogenes" <u>Cell</u> , 64:1129 (1991)	
	150	Hwang et al. "Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study", <u>Proc. Natl. Acad. Sci. USA</u> , 77: 4030 (1980)	
	151	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochim. Biophys. Acta</u> , 1198:165-184 (1994)	
	152	Ikegawa et al., "Isolation, characterization and chromosomal assignment of the human WNT7A gene" <u>Cytogenet Cell Genet</u> 74:149-152 (1996)	
	153	Johnson et al., "A month-long effect from a single injection of microencapsulated human growth hormone" <u>Nat. Med.</u> 2:795-799 (1996)	
	154	Jones et al., <u>Nature</u> , "Replacing the complementary-determining regions in a human antibody with those from a mouse" 321:522-525 (1986)	
	155	Jones, Elizabeth W., "Proteinase Mutants of Caccharomyces Cerevisiae" <u>Genetics</u> , 85:12 (1977)	
	156	Kantor et al., "Modulation of Carcinoembryonic Antigen Messenger RNA Levels in Human Colon Carcinoma Cells by Recombinant Human γ -Interferon" <u>Cancer Research</u> , 49(1):2651-5 (1989)	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
157	Karmali et al., "Prostaglandins in breast cancer: Relationship to disease stage and hormone status" <u>Br. J. Cancer</u> , 48:689-696 (1983)
158	Katoh et al., "Cloning expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family" <u>Oncogene</u> 13:873-876 (1996)
159	Kelly and Hynes, "Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans" <u>EMBO J.</u> , 4:475-479 (1985)
160	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> , 185:527-537 (1990)
161	Kikuchi et al., "The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of Escherichia coli" <u>Nucleic Acids Res.</u> 9:5671-5678 (1981)
162	Kim et al., "Anti4-1BB Monoclonal Antibodies Enhance Antitumor Efficacy of Adoptive Immunotherapy Using Tumor-Draining Lymph Node Cells" <u>Proc. Am. Assoc. Cancer Res.</u> 41, 91 Meet., 290, 2000 (Conference abstract: 91 st Annual Meeting of the American Association for Cancer research, San Francisco, California, USA, 2001)
163	Kingsman et al. "Replication In Saccharomyces cerevisiae of Plasmid Pbr313 Carrying DNA from the Yeast trpl Region", <u>Gene</u> , 7:141 (1979)
164	Kobayashi et al., "Mutations of the β-Catenin Gene in Endometrial Carcinomas" <u>Jpn. J. Cancer Res.</u> 90:55-9 (1999)
165	Koesters et al., "Mutational Activation of the β-Catenin Proto-Oncogene Is a Common Event in the Development of Wilms' Tumors" <u>Cancer Res.</u> 59:3880-2 (1999)
166	Koj et al. "Regulation of Synthesis of Some Proteinase Inhibitors in Human Hepatome Cells HepG2 by Cytokines, Hepatocyte Growth Factor" <u>Biol Chem Hoppe Seyler</u> 374:193-201 (1993)
167	Komine et al. "Genomic Organization and Physical Mapping of the Transfer RNA Genes in Escherichia coli K12", <u>J. Mol. Biol.</u> 212:579-598 (1990)
168	Korinek et al., "Two members of the Rcf family implicated in Wnt/β-Catenin signaling during Embryogenesis in the Mouse" <u>Mol. Cell Biol.</u> 18:1248-56 (1998)
169	Korinek et al., "Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC-/ Colon Carcinoma" <u>Science</u> 275:1784-1787 (1997)
170	Kostelný et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers", <u>J. Immunol.</u> 148(5):1547-1553 (1992)
171	Lako et al., "Isolation, characterization and embryonic expression of WNT11, a gene which maps the 11q13.5 and has possible roles in the development of skeleton, kidney and lung" <u>Gene</u> 219:101-110 (1998)
172	Lako et al., "Isolation and Characterization of WNT8B, a Novel Human Wnt Gene That Maps to 10q24" <u>Genomics</u> 35:386-388 (1996)
173	Lasko et al., "Targeted oncogene activation by site-specific recombination in transgenic mice" <u>Proc. Natl. Acad. Sci. USA</u> , 89:6232-636 (1992)
174	Lassam et al., "Synthesis of DNA, Late Polypeptides, and Infectious Virus by Host-Range Mutants of Aenovirus 5 in Nonpermissive Cells" <u>Virology</u> , 87:63-467 (1978)
175	Lavitrano et al., "Sperm Cells as vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice" <u>Cell</u> , 57:717-73 (1989)
176	Lee et al., "Complexes formed by (pyrimidine)n.(purine)n DNAs on lowering the pH are three-stranded" <u>Nucl. Acids Res.</u> , 6:3073 (1979)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 O P E R E INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(USE SEVERAL SHEETS IF NECESSARY)</i>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
177	Lee et al., "Cloning, Chromosomal Localization, and Tissue Expression of Autotaxin from human Teratocarcinoma Cells" <u>Biochem Biophys Res Commun</u> 218:714-719 (1996)
178	Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality" <u>Cell</u> , 69:915 (1992)
179	Lo, Cecilia W., "Transformation by Iontophoretic Microinjection of DNA: Multiple Integration Without Tandem insertions" <u>Mol. Cell Biol.</u> , 3:1803-1814 (1983)
180	Lonberg and Huszar, "Human Antibodies from transgenic Mice" <u>Intern. Rev. Immunol.</u> 13 65-93 (1995)
181	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications" <u>Nature</u> 368 856-859 (1994)
182	Louvencourt et al., "Transformation of Kluyveromyces lactis by Killer Plasmid DNA", <u>J. Bacteriol.</u> , 154(2): 737-1742 (1983)
183	Lucas et al., "High-Level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector" <u>Nucl. Acids Res.</u> 24(9):1774-1779 (1996)
184	Lutz-Freyermuth et al., "Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II OF U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> , 87:6393-6397 (1990)
185	Mansour et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes" <u>Nature</u> , 336:348-352 (1988)
186	Mantei et al., "Rabbit β-globin mRNA production in mouse L cells transformed with clone rabbit β-globin chromosomal DNA" <u>Nature</u> , 281:40-46 (1979)
187	Marasco et al. "Design, intracellular expression, and activity of a human anti-human Immunodeficiency virus type 1 gp120- single-chain antibody, <u>Proc. Natl. Acad. Sci. USA</u> , 90: 7889-7893 (1993)
188	Marks et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage" <u>J. Mol. Biol.</u> , 222:581 (1991)
189	Martin and Papahadjopoulos, "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles" <u>J. Biol. Chem.</u> , 257: 286-288 (1982)
190	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Current" <u>Science</u> , 255:192-194 (1992)
191	Martin-Satue, M. and Blanco, J., 'Identification of Semaphorin E Gene Expression in Metastatic Human Lung Adenocarcinoma Cells by mRNA Differential Display" <u>J Surg Oncol</u> 72:18-23 (1999)
192	Massey, " Catalytic antibodies catching on" <u>Nature</u> , 328:457-458 (1987)
193	Mather, Jennie P. "Establishment and Characterization of two Distinct Mouse Testicular Epithelial Cell Lines", <u>Biol. Reprod.</u> , 23:243-251 (1980)
194	McGrew et al., "Direct regulation of the Xenopus engrailed-2 promoter by the Wnt signaling pathway, and a molecular screen for Wnt-responsive genes, confirm a role for Wnt signaling during neural patterning in Xenopus" <u>Mech. Dev.</u> 87:21-32 (1999)
195	McWhirter et al., "Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia" <u>Proc Natl Acad Sci USA</u> 96:11464-11469 (1999)
196	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of Tetrapeptide" <u>J. Am. Chem. Soc.</u> , 85:2149-2154 (1963)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 O I P E J C A T DEC 03 2001 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

PATENT & EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
197	Miller and Moon, "Signal transduction through β-catenin and specification of cell fate during embryogenesis" <u>Genes & Dev.</u> 10:2527-2539 (1996)
198	Milstein and Cuello, "Hybrid hybridomas and their use in immunohistochemistry" <u>Nature</u> , 305:537-539 (1983)
199	Molenaar, et al., " XTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos" <u>Cell</u> 86:391-399 (1996)
200	Mordenti, J. and Chappell, W. "The use of interspecies scaling in toxicokinetics" In <u>Toxicokinetics and New Drug Development</u> , Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96
201	Morin et al., "Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC" <u>Science</u> 275:1787-1790 (1997)
202	Morrison, Sherrie L., "Success in specification" <u>Nature</u> 368, 812-13 (1994)
203	Moss, "Nomenclature of Retinoids" <u>Biochemical Nomenclature and Related Documents</u> , 2 nd edition, Portland Press, 1992, pp 247 -51
204	Moss , "Nomunclature of Retinoids" <u>Pure Appl. Chem.</u> , 55:721-726 (1983)
205	Moss, "Nomenclature of Retinoids" <u>Eur. J. Biochem.</u> , 129:1-5 (1982)
206	Moss, "Nomenclature of Retinoids" <u>J. Biol. Chem.</u> , 258:5329-5333 (1983)
207	Moss, G.P., "Nomenclature of Retinoids" <u>Arch. Biochem. Biophys.</u> , 224:728-731 (1983)
208	Murata et al., " cDNA Cloning of the Human Tumor Motility-stimulating Protein, Autotaxin, Reveals a Homology with Phosphodiesterases" <u>J Biol Chem</u> 269:30479-84 (1994)
209	Nagasawa et al., "Cloning of the cDNA for a New Member of the Immunoglobulin Superfamily (ISLR) Containing Leucine-Rich Repeat (LRR)" <u>Genomics</u> 44:273-279 (1997)
210	Nagasawa et al., "Human and Mouse ISLR (Immunoglobulin Superfamily) Containing Leucine-Rich Repeat)Genes: Genomic Structure and Tissue Expression" <u>Genomics</u> 61:37-43 (1999)
211	Nam et al., "Autotaxin 9ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells" <u>Oncogene</u> 19:241-247 (2000)
212	Neuberger et al., "Recombinant antibodies possessing novel effector functions" <u>Nature</u> , 312:604-608 (1984)
213	Neuberger, Michael, "Generating high-avidity human Mabs in mice" <u>Nature Biotechnology</u> 14, 826 (1996)
214	Nusse and Varmus, "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome" <u>Cell</u> 31:99-109 (1982)
215	Nygren, Hakan "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>J. Histochem. and Cytochem.</u> , 30:407 (1982)
216	Paborsky et al., "Mammalian cell transient expression of tissue factor for the production of antigen" <u>Protein Engineering</u> , 3(6):547-553 (1990)
217	Pain an Surolia "Preparation of Protein A-Peroxidase Monoconjugate using a Heterobifunctional Reagent, and its use in Enzyme Immunoassays" <u>J. Immunol. Meth.</u> , 40:219 (1981)
218	Palacios and Hamallo, "Mutations in the β-Catenin Gene(CTNNB1) in Endometrioid Ovarian Carcinomas" <u>Cancer Res</u> 58:1344-7 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

PATENT & TRADEMARK EXAMINER INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
219	Palladino et al. "Characterization of the Antitumor Activities of Human Tumor Necrosis Factor- α and the Comparison with other Cytokines: Induction of Tumor-Specific Immunity", <u>J. Immunol.</u> , 138:4023-4032 (1987)
220	Pearson, D. and Sasse, J., "Differential Regulation of Biglycan and Decorin by Retinoic Acid in Bovine Chondrocytes" <u>J Biol Chem</u> 267:25364-25370 (1992)
221	Peifer and Polakis, "Wnt Signaling in Oncogenesis and Embryogenesis- A Look Outside the Nucleus" <u>Science</u> 287:1606-1609 (2000)
222	Pennica et al., "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors" <u>Proc. Natl. Acad. Sci USA</u> 95:14717-22 (1998)
223	Perry, M.C., Ed., <u>Chemotherapy Source Book</u> , Williams & Wilkins, Baltimore, MD (1992)
224	Polakis, Paul, "Wnt signaling and cancer" <u>Genes Dev</u> 14:1837-1851 (2000)
225	Polakis, Paul, "The oncogenic activation of β -catenin" <u>Curr. Opin. Genet. Dev.</u> 9:15-21 (1999)
226	Presta, Leonard G. , "Antibody engineering" <u>Curr. Op. Struct. Biol.</u> , 2:593-596 (1992)
227	Prete et al., "Drug-Induced Changes of Carcinoembryonic Antigen Expression in Human Cancer Cells: Effect of 5-Fluorouracil" <u>Journal of Pharmacology and Experimental Therapeutics</u> 279(3):1574-81 (1996)
228	Rankin et al., "Partial cloning and assignment of WNT6 to human chromosome band 2q35 by in situ hybridization" <u>Cytogenet Cell Genet</u> 84:50-52 (1999)
229	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review" <u>Gene</u> , 159:19-27 (1995)
230	Reichmann et al., "Reshaping human antibodies for therapy" <u>Nature</u> , 332:323-329 (1988)
231	Rimm et al., "Frequent Nuclear/Cytoplasmic Localization of β -Catenin without Exon 3 Mutations in Malignant Melanoma" <u>Am. J. Pathol.</u> 154:325-9 (1999)
232	Rochette-Egly et al., "The AF-1 and AF-2 Activating Domains of Retinoic Acid Receptor- α (RAR- α) and Their Phosphorylation Are Differentially Involved in Parietal Endodermal Differentiation of F9 Cells and Retinoid-Induced Expression of Target Genes" <u>Mol. Endocrinol.</u> 14(9):1398-1410 (2000)
233	Roelink et al., "Molecular Cloning and Chromosomal Localization to 17q21 of the Human WNT3 Gene" <u>Genomics</u> 17:790-792 (1993)
234	Roose et al., "Synergy Between Tumor Suppressor APC and the β -Catenin-Tcf4 target Tcf1" <u>Science</u> 285:1923-1926 (1999)
235	Rossi, John J., "Making ribozymes work in cells" <u>Current Biology</u> , 4:469-471 (1994)
236	Rubinfeld et al., "Association of the APC Gene Product with β -Catenin" <u>Science</u> 262:1731-1734 (1993)
237	Rubinfeld et al., "Association of the APC Gene Product with β -Catenin" <u>Science</u> 262:1731-1734 (1993)
238	Rubinfeld et al., "Stabilization of β -Catenin by Genetic Defects in Melanoma Cell Lines" <u>Science</u> 275:1790-1792 (1997)
239	Ruppert et al., "Cloning and expression of human TAD..250" a TBP-associated factor implicated in cell-cycle regulation" <u>Nature</u> , 362:175-179 (1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT O P E S C DEC 03 2001 USE SEVERAL SHEETS IF NECESSARY	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
240	Sakanaka, et al., "New steps in the Wnt/beta-catenin signal transduction pathway" "Recent Prog Horm Res 55:225-36 (2000)		
241	Sambrook et al., <u>Molecular Cloning: A Laboratory Manual</u> (New York: Cold Spring Harbor Laboratory Press, 1989)		
242	Scholtissek and Grosse, "A cloning cartridge of λ t0 terminator" <u>Nucleic Acids Res.</u> 15:3185 (1987)		
243	Schwab et al. "Amplification of Cellular Oncogenes: A Predictor of Clinical outcome in Human Cancer", <u>Genes Chromosomes Cancer</u> , 1:181-193 (1990)		
244	Scopes, Robert K., <u>Protein Purification: Principles and Practice</u> , Springer-Verlag, New York (1982)		
245	Scott et al., "Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CEASER trial" <u>The Lancet</u> , 349(9063) pSH19(4) (May 17, 1997)		
246	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>J. Exp. Med.</u> 175:217-225 (1992)		
247	Shopes, Bob, "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity" <u>J. Immunol.</u> , 148: 2918:2922 (1992)		
248	Slamon et al., "Human Breast Cancer" Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> , 235:177-182 (1987)		
249	Small et al., "Analysis of a Transgenic Mouse Containing Simian Virus 40 and v-myc Sequences" <u>Mol. Cell. Biol.</u> , 5:642-648 (1985)		
250	Sojar and Bahl, et al., "A Chemical Method for the Deglycosylation of Proteins", <u>Arch. Biochem. Biophys.</u> , 259:52-57(1987)		
251	Sompanyrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci.</u> , 75:7575 (1981)		
252	Sreekrishna et al., "High level expression of heterologous proteins in methylotrophic yeast Pichia pastoris" <u>J. Basic Microbiol.</u> , 28:265-278 (1988)		
253	Stella et al., "Prodrugs: A Chemical Approach to Targeted Drug Delivery", University of Kansas and Interx Research Corp., Lawrence, Kansas 66045		
254	Stevenson et al. "A chimeric antibody with dual Fc regions (bisFcFc) prepared by manipulations at the IgG hinge", <u>Anti-Cancer Drug Design</u> , 3: 219-230 (1989)		
255	Stewart et al., "An STS-Based Radiation Hybrid Map of the Human Genome" <u>Genome Research</u> , 7:422-433 (1997)		
256	Stewart et al., <u>Solid-Phase Peptide Synthesis</u> , W.H. Freeman Co., San Francisco, CA (1969)		
257	Stinchcomb et al., "Isolation and characterization of yeast chromosomal replicator" <u>Nature</u> , 282:39 (1979)		
258	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> , 121:210 (1986)		
259	Szeto et al., "Overexpression of the Retinoic Acid-Responsive Gene Stra6 Human Cancers and Its Synergistic Induction by Wnt-1 and Retinoic Acid" <u>Cancer Research</u> 61:4197-4250 (May 15, 2001)		
260	Taneja et al., "Reexpression of retinoic acid receptor (RAR) γ or overexpression of RAR α or RAR β in RAR γ -null F9 cells reveals a partial functional redundancy between the three RAR types" <u>Proc. Natl. Acad. Sci. USA</u> 92:7854-8 (1995)		

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT DEC 03 2001 (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER & TRADEMARK OFFICE INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	261	Tetsu and McCormick, "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells" <u>Nature</u> 398:422-426 (1999)	
	262	Thimmappaya et al., "Adenovirus VAI RNA Is Required for Efficient Translation of Viral mRNAs at Late Times after infection" <u>Cell</u> , 31:543 (1982)	
	263	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> , 51:503 (1987)	
	264	Thomas, Patricia S., "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> , 77:5201-5205 (1980)	
	265	Thompson et al., "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells" <u>Cell</u> , 56:313-321 (1989)	
	266	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> , 138:350 (1987)	
	267	Tilburn et al. "Transformation by Integration in Aspergillus nidulans", <u>Gene</u> , 26:205-221 (1983)	
	268	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells" <u>EMBO J</u> , 10:3655-3659 (1991)	
	269	Tremblay et al., "Retinoic Acid Stimulates the Expression of 11β-Hydroxysteroid Dehydrogenase Type 2 in Human Choriocarcinoma JEG-3 Cells" <u>Biol Reprod</u> 60:541-545 (1999)	
	270	Tschumper et al., "Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene" <u>Gene</u> , 10:157 (1980)	
	271	Tsukamoto et al., "Expression of the int-1 Gene in Transgenic Mice Is Associated with Mammary Gland Hyperplasia and Adenocarcinomas in Male and Female Mice" <u>Cell</u> 55:619-625 (1988)	
	272	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> , 77:4216 (1980)	
	273	Van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences" <u>BioTechniques</u> 6:958 (1988)	
	274	Van der Putten et al., "Efficient insertion of genes into the mouse germ line via retroviral vectors" <u>Proc. Natl. Acad. Sci. USA</u> , 82:6148-615 (1985)	
	275	Van Ooyen et al., "The nucleotide sequence of the human int-1 mammary oncogene; evolutionary conservation of coding and non-coding sequences" <u>EMBO J</u> 4:2905-9 (1985)	
	276	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> , 130:946 (1977)	
	277	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> , 239:1534-1536 (1988)	
	278	Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> , 238: 1098 (1987)	
	279	Wade, D. P. and Owen, J. S., "Regulation of the cholesterol efflux gene, ABCA1" <u>Lancet</u> 357:161-163 (2001)	
	280	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci. USA</u> 87, 3410-3414 (1990)	
	281	Wainwright et al., "Isolation of a human gene with protein sequence similarity to human and murine int-1 and the Drosophila segment polarity mutant wingless" <u>EMBO J</u> 7:1743-1748 (1988)	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 O I P E DEC 03 2001 PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)		
	282 Warzocha and Wotowiec, "Antisense strategy" biological utility and prospects in the treatment of hematological malignancies." <u>Leuk. Lymphoma</u> 24:267-281 (1997)		
	283 Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London SerA</u> , 317:415-423 (1986)		
	284 Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites" <u>Gene</u> , 34:315 (1985)		
	285 Willert et al., "Wnt-induced dephosphorylation of Axin releases β-catenin from the Axin complex" <u>Genes Dev.</u> 13:1768-73 (1999)		
	286 Wilman, Derry E., "Prodrugs in Cancer Chemotherapy", <u>Biochemical Society Transactions</u> , 14:375-382, 615th Meeting, Belfast (1986)		
	287 Wodarz and Nusse, "Mechanisms of WNT Signaling in Development" <u>Annu Rev Cell Dev Biol</u> 14:59-88 (1998)		
	288 Wodicka et al., "Genome-wide expression monitoring in <i>Saccharomyces cerevisiae</i> ", <u>Nat Biotechnol</u> 15:1359-1367 (1997)		
	289 Wong et al. "Differential Transformation of Mammary Epithelial Cells by Wnt Genes" <u>Mol Cell Biol</u> 14:6278-6286 (1994)		
	290 Wright et al., "β-Catenin mutation and expression analysis on ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours" <u>Int. J. Cancer</u> 82:625-9 (1999)		
	291 Wu et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System" <u>J. Biol. Chem.</u> 262, 4429-4432 (1987)		
	292 Xiang et al., "Expression of Co-stimulatory 4-1BB Ligand Induces Significant Tumor Regression and Protective Immunity" <u>Cancer Biotherapy and Radiopharmaceuticals</u> , 14(5):353-361 (1999)		
	293 Yamada et al. , "Identification of semaphorin E as non-MDR drug resistance gene of human cancers" <u>Proc Natl Acad Sci U S A</u> 94: 14713-14718 (1997)		
	294 Yelton et al., "Transformation of <i>Aspergillus nidulans</i> by using trpCplasmid" <u>Proc. Natl. Acad. Sci. USA</u> , 81: 1470-1474 (1984)		
	295 Zacharski, Leo R., "Basis for Selection of Anticoagulant Drugs for Therapeutic Trials in Human Malignancy" <u>Haemostasis</u> , 16:300-320 (1986)		
	296 Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type I9II in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci. USA</u> 83:4143-4146 (1986)		
	297 Zapata et al., "Engineering linear F(ab')2 fragments for efficient production in <i>Escherichia coli</i> and enhanced antiproliferative activity" <u>Protein Eng.</u> 8(10):1057-1062 (1995)		
	298 Zhang et al., "The Retinoic Acid and cAMP-dependent Up-regulation of 3-O-Sulfotransferase-1 Leads to a Dramatic Augmentation of Anticoagulantly Active Heparan Sulfate Biosynthesis in F9 Embryonal Carcinoma Cells" <u>J Biol Chem</u> 273:27998-28003 (1998)		
	299 Zhang et al., "Gene Expression Profiles in Normal and Cancer Cells" <u>Science</u> 276:1268-1272 (1997)		
	300 Ziemer et al., "Identification of a Mouse Homolog of the Human BTEB2 Transcription Factor as a β-Catenin-Independent Wnt-1 Responsive Gene" <u>Mol Cell Biol</u> 21:562-574 (2001)		

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.83A	APPLICATION NO. 09/901,812
		APPLICANT Pennica et al	
		FILING DATE July 10, 2001	GROUP 1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	301	Zola, Heddy , <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Inc. (1987) pp. 147-158
	302	Zupi et al. "Cloning in Vitro and in Vivo of Lewis Lung Carcinoma: Properties and Characteristics", <u>Br. J. Cancer</u> , 41:suppl. 4:309 (1980)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	